Table 2 Overview of 1st- and 2nd-line treatments during the study period, mRCC patients, Estonia 2004–2012
From: Changes in therapy and survival of metastatic renal cell carcinoma in Estonia
2004–2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2008–2012 | 2004–2012 | |
|---|---|---|---|---|---|---|---|---|
First line treatment | 137 | 26 | 50 | 47 | 58 | 62 | 243 | 380 |
Immunotherapy INFa (%) | 137 (100) | 24 (92) | 24 (48) | 2 (4) | 2 (3) | 1 (2) | 53 (22) | 207 (55) |
Targeted therapy (%) | 0 (0) | 2 (8) | 26 (52) | 45 (96) | 56 (97) | 61 (98) | 190 (78) | 190 (50) |
INFa+Bevacizumab | 0 | 1 | 7 | 17 | 14 | 12 | 51 | 51 (13) |
Sunitinib | 0 | 0 | 16 | 26 | 38 | 42 | 122 | 122 (32) |
Sorafenib | 0 | 1 | 1 | 1 | 2 | 0 | 5 | 5 (1) |
Temsirolimus | 0 | 0 | 2 | 1 | 2 | 4 | 9 | 9 (2) |
Pazopanib | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 (1) |
Second line treatment | 4 | 15 | 21 | 23 | 24 | 18 | 101 | 105 |
Immunotherapy INFa (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (6) | 1 (1) | 1 (1) |
Targeted therapy (%) | 4 (100) | 15 (100) | 21 (100) | 23 (100) | 24 (100) | 17 (94) | 100 (99) | 104 (99) |
INFa+Bevacizumab | 0 | 0 | 0 | 1 | 2 | 4 | 7 | 7 (7) |
Sunitinib | 0 | 0 | 2 | 3 | 7 | 1 | 13 | 13 (12) |
Sorafenib | 2 | 15 | 18 | 17 | 12 | 12 | 74 | 76 (72) |
Temsirolimus | 0 | 0 | 1 | 2 | 1 | 0 | 4 | 4 (4) |
Pazopanib | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 (2) |
Everolimus | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 2 (2) |